Cambrian Biopharma has backed a round that will go toward further developing Vita’s lead candidate, VTA-110, for muscular dystrophy treatments.

US-based cell engineering developer Vita Therapeutics has secured $20m in a round led by ageing research group Cambrian Biopharma, Baltimore Business Journal has reported. Spun out of Johns Hopkins University in 2019, Vita is working on stem cells that can contribute to muscle regeneration in patients suffering from muscular dystrophy – a type of genetic…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.